Trials / Completed
CompletedNCT00157534
A Study to Evaluate the Safety and Efficacy of Celgosivir in Patients With Chronic Hepatitis C Genotype 1 Infection
A Phase II, Randomised, Dose-Ranging, Open-Label, Multi-Centre Study to Evaluate the Safety and Efficacy of Celgosivir for 12 Weeks in Patients With Chronic Hepatitis C Infection
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 43 (planned)
- Sponsor
- BioWest Therapeutics Inc · Industry
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
The objective of the study is to evaluate the safety and efficacy of celgosivir for 12 weeks in patients with chronic hepatitis C genotype 1 infection.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Celgosivir |
Timeline
- Start date
- 2004-10-01
- Completion
- 2005-08-01
- First posted
- 2005-09-12
- Last updated
- 2005-09-12
Source: ClinicalTrials.gov record NCT00157534. Inclusion in this directory is not an endorsement.